Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Development of formulations of sorafenib tosylate for improved biopharmaceutical potential
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: SHARMA, Teenu (Panjab University, University institute of Pharmaceutical sciences)
- Co-author(s): Teenu Sharma: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
Atul Jain: UGC-CoE ANNN, Panjab University, Chandigarh, India
O P Katare: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
Bhupinder Singh: UGC-CoE ANNN, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
Sorafenib tosylate, BCS class II anticancer drug, exhibits low oral bioavailability (8%) ostensibly owing to poor aqueous solubility, high first-pass effect and P-gp efflux.
MethodsThe patient-centric quality target product profile (QTPP) and critical quality attributes (CQAs) were earmarked. Ishikawa Fish-bone diagram was constructed.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019